Quercetin-induced apoptosis of HT-29 colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis

Molecular Medicine Reports

Volumn 14, Issue 5, 2016, Pages 4559-4566

  Yang, Lin ^a,b   Liu, Yanqing ^a,b   Wang, Mei ^a   Qian, Yayun ^a,b   Dong, Xiaoyun ^a,b   Gu, Hao ^a,b   Wang, Haibo ^a,b   Guo, Shiyu ^c   Hisamitsu, Tadashi ^c  

^a YANGZHOU UNIVERSITY   (China)

^b Jiangsu Key Lab of Intgd Traditional Chinese and W Med for Prev and Treatm of Senile Diseases   (China)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; CSN6; HT 29 colon cancer cells; Myc; Quercetin

Indexed keywords

COP9 SIGNALOSOME; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; PROTEIN P53; QUERCETIN; AKT1 PROTEIN, HUMAN; COPS6 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL VIABILITY; CHROMATIN CONDENSATION; COLON CANCER; DRUG MECHANISM; FLOW CYTOMETRY; HT 29 CELL LINE; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOGENESIS; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HT-29 CELL LINE; PATHOLOGY; PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84992332908     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5818     Document Type: Article

References (39)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Hirpara KV, Aggarwal P, Mukherjee AJ, Joshi N and Burman AC: Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer Agents Med Chem 9: 138-161, 2009.
3. Tan WF, Lin LP, Li MH, Zhang YX, Tong YG, Xiao D and Ding J: Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol 459: 255-262, 2003.
4. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM and Aggarwal BB: Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 76: 1044-1063, 2010.
5. Murakami A, Ashida H and Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett 269: 315-325, 2008.
6. Kawahara T, Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Nara N and Tohda S: Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res 29: 4629-4632, 2009.
7. Luo H, Jiang BH, King SM and Chen YC: Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer 60: 800-809, 2008.
8. Vidya PR, Senthil MR, Maitreyi S, Ramalingam K, Karunagaran D and Nagini S: The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kappaB inhibition. Eur J Pharmacol 649: 84-91, 2010.
9. Suolinna EM, Buchsbaum RN and Racker E: The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res 35: 1865-1872, 1975.
10. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, Bertoncelli L, Cooper EL and Cossarizza A: Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011: 591356, 2011.
11. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP and Williams RL: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine. Mol Cell 6: 909-919, 2000.
12. Triantafyllou A, Mylonis I, Simos G, Bonanou S and Tsakalof A: Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 44: 657-670, 2008.
13. Deng XW, Dubiel W, Wei N, Hofmann K and Mundt K: Unified nomenclature for the COP9 signalosome and its subunits: An essential regulator of development. Trends Genet 16: 289, 2000.
14. Zhao RY, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, et al: Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest 121: 851-865, 2011.
15. Choi HH, Gully C, Su CH, Velazquez-Torres G, Chou PC, Tseng C, Zhao R, Phan L, Shaiken T, Chen J, et al: COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3sigma. Oncogene 30: 4791-4801, 2011.
16. Lee MH, Zhao R, Phan L and Yeung SC: Roles of COP9 signalosome in cancer. Cell cycle 10: 3057-3066, 2011.
17. Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM: Mdm2 is a ring finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951, 2000.
18. Inuzuka H, Fukushima H, Shaik S and Wei W: Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. Oncotarget 1: 685-690, 2010.
19. Xue Y, Chen J, Choi HH, Phan L, Chou PC, Zhao R, Yang H, Santiago J, Liu M, Yeung GE, et al: HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell cycle 11: 4181-4190, 2012.
20. Chen J, Shin JH, Zhao R, Phan L, Wang H, Xue Y, Post SM, Ho Choi H, Chen JS, Wang E, et al: CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun 5: 5384, 2014.
21. Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J and Watson J: c-myc oncogene expression in colorectal cancer. Cancer 59: 1289-1295, 1987.
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
23. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
24. Harborne JB and Williams CA: Advances in flavonoid research since 1992. Phytochemistry 55: 481-504, 2000.
25. Hirpara KV, Aggarwal P, Mukherjee AJ, Joshi N and Burman AC: Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anti-Cancer Agents Med Chem 9: 138-161, 2009.
26. Zhao D, Beiring B and Glorius F: Ruthenium-NHC-catalyzed asymmetric hydrogenation of flavones and chromones: General access to enantiomerically enriched flavanones, flavanols, chromanones and chromanols. Angew Chem Int Ed Engl 52: 8454-8458, 2013.
27. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al: Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17: 61-75, 2013.
28. Veeriah S, Kautenburger T, Habermann N, Sauer J, Dietrich H, Will F and Pool-Zobel BL: Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics. Mol Carcinog 45: 164-174, 2006.
29. Kim HJ, Kim SK, Kim BS, Lee SH, Park YS, Park BK, Kim SJ, Kim J, Choi C, Kim JS, et al: Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J Agric. Food Chem 58: 8643-8650, 2010.
30. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK and Lee HY: Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 67: 11630-11639, 2007.
31. Su RY, Chao Y, Chen TY, Huang DY and Lin WW: 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL-and TNF(alpha)-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther 6: 1562-1571, 2007.
32. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM and Park OJ: Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 247: 115-121, 2007.
33. Eriksson A, Kalushkova A, Jarvius M, Hilhorst R, Rickardson L, Kultima HG, de Wijn R, Hovestad L, Fryknäs M, Öberg F, et al: AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia. Biochem Pharmacol 87: 284-291, 2014.
34. Hu ZY, Sun J, Zhu XF, Yang D and Zeng YX: ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. J Transl Med 7: 74, 2009.
35. Wang K, Liu R, Li J, Mao J, Lei Y, Wu J, Zeng J, Zhang T, Wu H, Chen L, et al: Quercetin induces protective autophagy in gastric cancer cells: Involvement of Akt-mTOR-and hypoxia-induced factor 1mediated signaling. Autophagy 7: 966-978, 2011.
36. Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Research 1: 1001-1008, 2003.
37. Mayo LD and Dormer DB: The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 27:462-467, 2002.
38. Maurya AK and Vinayak M: Quercetin regresses dalton's lymphoma growth via suppression of PI3K/AKT signaling leading to upregulation of p53 and decrease in energy metabolism. Nutr Cancer 67: 354-363, 2015.
39. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982, 2001.